<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1000">
  <stage>Registered</stage>
  <submitdate>16/01/2006</submitdate>
  <approvaldate>7/06/2006</approvaldate>
  <actrnumber>ACTRN12606000232538</actrnumber>
  <trial_identification>
    <studytitle>The early use of IV (Intra venous)verapamil and nitrates in Acute Myocardial Infarction (AMI)</studytitle>
    <scientifictitle>The early use of Intra Venous verapamil and nitrates and the effects on angiographic patency and infarct size in Acute Myocardial Infarction</scientifictitle>
    <utrn />
    <trialacronym>IVANA</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Acute ST segment elevation myocardial infarction requiring urgent revascularisation (angioplasty or stent). The ST segment refers to that of QRST complex as represented on a 12 lead ECG(electrocardiogragh)</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>IV verapamil 2 mg over 5 minutes or saline placebo and glyceryl trinitrate infusion 5mcg per minute( 8 mls per hour) and the patient has given informed consent.</interventions>
    <comparator>Corresponding saline placebo is administered as soon as the decision for acute intervention(angioplasty or stent) has been made</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Angiographic TIMI-3 (term used to state that blood flow through coronary artery is back to normal) flow at time of angiograghy</outcome>
      <timepoint>An Xray -angiogram-is taken of the coronary artery at the start of the procedure  to see which arteies are blocked and need an  angioplasty or stent and which ones are open and do not  require treatment.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Angiographic patency and infarct size measured at time of angiography.(An Xray- angiogram- is taken of the coronary artery at the start of the procedure  to see which arteies are blocked and need an angioplasty or stent and which ones are open and do not  require treatment).</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Acute ST segment elevation myocardial infarction(STEMI) with primary Percutaneous Coronary Intervention.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Contraindications to verapamil/glyceryl trinitrate.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Blinded,numbered and sealed treatment boxes allocated by number sequential randomisation</concealment>
    <sequence>Permuted blocks</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>1/10/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>300</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>The Queen Elizabeth Hospital,Cardiology Unit</primarysponsorname>
    <primarysponsoraddress>Adelaide SA</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>National Heart Foundation of Australia Grant in Aid</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To assess if the early use of verapamil and Glyceryl trinitrate improves TIMI 3 flow(term used to state that blood flow through coronary artery is back to normal)Only the study pharmacist was unblinded to treatment allocation. Study drug was sealed in a box and allocated a number in lots of 10. Study staff would allocate the sealed box to the patient by number sequence. All study personel and persons involved in the clinical management of the patient were also blinded to treatment allocation.Emergency unblinding was available if required.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Queen Elizabethn Hospital,Cardiology Unit</ethicname>
      <ethicaddress>AdelaideSA </ethicaddress>
      <ethicapprovaldate>24/02/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Lyell McEwin Health Service</ethicname>
      <ethicaddress>Adelaide SA </ethicaddress>
      <ethicapprovaldate>6/10/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Flinders Medical Centre</ethicname>
      <ethicaddress>Adelaide</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital</ethicname>
      <ethicaddress>Adelaide</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr John Beltrame</name>
      <address>The Queen Elizabeth Hospital
28 Woodville Rd
Woodville SA 5011</address>
      <phone>+61 8 82226000</phone>
      <fax>+61 8 82227021</fax>
      <email>marilyn.black@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr John Beltrame</name>
      <address>The Queen Elizabeth Hospital
28 Woodville Rd
Woodville SA 5011</address>
      <phone>+61 8 82226000</phone>
      <fax>+61 8 82227021</fax>
      <email>sue.leslie@nwahs.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Marilyn Black</name>
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>